曲贝替定联合奥拉帕利对比曲贝替定治疗蒽环类失败后晚期软组织肉瘤的随机II期研究(TOMAS2)
TOMAS2是一项由意大利肉瘤组开展的随机II期研究,纳入130例蒽环类治疗后进展的晚期软组织肉瘤患者,随机接受曲贝替定联合奥拉帕利或曲贝替定单药。联合组6个月无进展生存率为32%对比28%(HR 0.722,P=0.081),达到预设P<0.10的统计学显著性阈值但总体获益有限。PARP1表达阳性和子宫平滑肌肉瘤亚组从联合治疗中获益更明显。
要点
- 联合组6个月PFS率32%对比28%,HR 0.722,P=0.081,达到预设阈值但总体获益有限
- PARP1表达者联合组中位PFS 4.3个月对比2.5个月,HR 0.537,P=0.009
- 子宫平滑肌肉瘤亚组12个月PFS联合组42.9%对比单药组0%
核心结论
- 曲贝替定联合奥拉帕利在总体晚期软组织肉瘤人群中获益有限,但PARP1表达者和子宫平滑肌肉瘤亚组显示显著获益。
研究设计与样本
- 研究者发起的开放标签随机II期试验,纳入130例蒽环类治疗后进展的晚期软组织肉瘤成人患者,1:1随机分配。
- 随机按组织学类型(L-肉瘤对比非L-肉瘤)和既往治疗线数(一线对比二线及以上)分层。
- 联合组接受曲贝替定1.1 mg/m2每21天静脉注射联合奥拉帕利片150 mg每日两次;单药组接受曲贝替定1.5 mg/m2每21天静脉注射。
主要发现
- 中位随访37.4个月,联合组6个月PFS率32%(95%CI 22%-46%),单药组28%(95%CI 19%-42%),HR 0.722(95%CI 0.501-1.041,P=0.081)。
- 联合组中位PFS 3.9个月(95%CI 2.7-5.2),单药组2.9个月(95%CI 2.2-3.6)。
- 126例可评估患者中,客观缓解率联合组12.7%(95%CI 6.1%-22.7%),单药组7.9%(95%CI 3.0%-16.7%),OR 1.60(95%CI 0.50-5.16,P=0.43)。
- PARP1表达与联合组PFS改善显著相关:6个月PFS率41.5%对比27.8%,中位PFS 4.3个月对比2.5个月,HR 0.537(95%CI 0.337-0.855,P=0.009)。
- 子宫平滑肌肉瘤亚组12个月PFS联合组42.9%,单药组0%。
关键数值与推荐
- 主要终点为RECIST1.1评估的6个月无进展生存率(PFS6m)。
- 联合组≥3级血液学毒性显著更常见。
临床怎么用
- 对于PARP1表达的晚期软组织肉瘤和子宫平滑肌肉瘤患者,曲贝替定联合奥拉帕利可作为潜在治疗选择。
- 治疗决策应结合组织学亚型和PARP1等生物标志物,而非在所有软组织肉瘤中普遍使用联合方案。
局限性
- 总体人群获益有限,主要终点仅达到预设的宽松显著性阈值(P<0.10)。
- 联合组≥3级血液学毒性显著增加。
- 亚组分析样本量小,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced/metastatic soft tissue sarcomas (STSs) remain an unmet clinical need. We previously reported the feasibility and preliminary activity of trabectedin-olaparib combination in patients with advanced STS progressing after anthracycline-based regimens. PATIENTS AND METHODS: In this investigator-initiated, open-label, phase II randomized trial, adult patients with advanced STS progressing after one or more prior lines of therapy, including at least one anthracycline-based regimen, were randomly assigned 1 : 1 to trabectedin 1.1 mg/m2 every 21 days (q21d) intravenous (i.v.) plus olaparib tablets 150 mg twice a day, or trabectedin 1.5 mg/m2 q21d i.v. Randomization stratified patients by histology (L-sarcoma, i.e. leiomyosarcoma and liposarcoma versus non-L-sarcoma) and number of prior therapies (one versus two or more). The primary endpoint was progression-free survival (PFS) rate at 6 months (PFS6m) per RECIST1.1. Secondary endpoints included PFS, overall survival (OS), RECIST1.1 overall response rate (ORR), and safety. Exploratory endpoints encompassed biomarker/molecular analyses. RESULTS: Between 25 May 2020 and 2 November 2022, 130 patients were enrolled at 13 Italian Sarcoma Group centers (81 female; 67 L-sarcoma; 93 one prior line). With a median follow-up of 37.4 months, PFS6m and median PFS were 32% [95% confidence interval (CI) 22% to 46%] and 3.9 months (95% CI 2.7-5.2 months) with trabectedin-olaparib versus 28% (95% CI 19% to 42%) and 2.9 months (95% CI 2.2-3.6 months) with trabectedin [hazard ratio (HR) 0.722, 95% CI 0.501-1.041, P = 0.081]. Among 126 assessable patients, ORR was 12.7% (95% CI 6.1% to 22.7%) versus 7.9% (95% CI 3.0% to 16.7%), respectively (odds ratio 1.60, 95% CI 0.50-5.16, P = 0.43). In the uterine leiomyosarcoma subgroup, 12-month PFS was 42.9% with trabectedin-olaparib versus 0% with trabectedin. PARP1 expression significantly correlated with improved PFS with trabectedin-olaparib (PFS6m and median PFS were 41.5% and 4.3 months versus 27.8% and 2.5 months; HR 0.537, 95% CI 0.337-0.855, P = 0.009). Grade ≥3 hematological toxicities were significantly more frequent with trabectedin-olaparib. CONCLUSIONS: Although trabectedin-olaparib combination reached the prespecified threshold for statistical significance for PFS (P < 0.10), the benefit was marginal in the all-comers STS population. Nonetheless, patients affected by PARP1-expressing STS and uterine leiomyosarcoma derived substantial benefit from the combination, supporting further histology- and biomarker-driven investigation in these settings.
引用
- D'Ambrosio L, Merlini A, Brunello A, et al. Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group. Ann Oncol. 2025. PMID: 41354211. doi:10.1016/j.annonc.2025.11.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。